Département médullaire, centre Calvé, 72, esplanade Parmentier, 62600 Berck-sur-Mer, France.
Ann Phys Rehabil Med. 2009 Mar;52(2):188-93. doi: 10.1016/j.rehab.2008.12.002. Epub 2009 Jan 22.
In spite of all the scientific advances in pharmacological research, a great number of patients cannot efficiently manage their chronic pain with conventional pharmacological treatments. Brain stimulation techniques have considerably improved these last 10 years. These techniques could be an interesting option after a rigorous selection of patients. We aim to evaluate the efficacy of brain stimulation (deep brain stimulation [DBS] and motor cortex stimulation [MCS]) within the framework of neuropathic pain management in spinal cord injury (SCI) patients and elaborate some recommendations.
The methodology used, proposed by the French Society of Physical Medicine and Rehabilitation (SOFMER), includes a systematic review of the literature, the gathering of information regarding current clinical practices and a validation by a multidisciplinary panel of experts.
DBS is more effective on nociceptive pain than deafferentation pain. For the central pain of SCI patients, the long-term efficacy of DBS is quite low (three patients out of 19, amounting to 16%). MCS seems to have an interesting potential with a long-term efficacy of 57% (four patients out of seven), with less complications than DBS.
For central pain in SCI patients, there is no sufficient level of evidence to validate the use of DBS. There is however a low level of evidence for MCS. These results must be validated by larger comparative or controlled versus placebo clinical studies.
尽管在药理学研究方面取得了所有这些科学进步,但仍有大量患者无法通过常规的药物治疗有效地控制其慢性疼痛。脑刺激技术在过去 10 年中得到了极大的改善。这些技术可以成为对患者进行严格选择后的一个有趣选择。我们旨在评估脑刺激(深部脑刺激[DBS]和运动皮层刺激[MCS])在脊髓损伤(SCI)患者的神经性疼痛管理框架内的疗效,并制定一些建议。
法国物理医学和康复学会(SOFMER)提出的方法包括对文献进行系统回顾、收集有关当前临床实践的信息以及由多学科专家小组进行验证。
DBS 对伤害性疼痛的效果优于去传入性疼痛。对于 SCI 患者的中枢性疼痛,DBS 的长期疗效相当低(19 例患者中有 3 例,占 16%)。MCS 似乎具有很大的潜力,长期疗效为 57%(7 例患者中有 4 例),并发症比 DBS 少。
对于 SCI 患者的中枢性疼痛,没有足够的证据来验证 DBS 的使用。然而,MCS 的证据水平较低。这些结果需要通过更大的比较或对照安慰剂的临床试验来验证。